SG11202101042SA - Gene therapy methods to control organ function - Google Patents
Gene therapy methods to control organ functionInfo
- Publication number
- SG11202101042SA SG11202101042SA SG11202101042SA SG11202101042SA SG11202101042SA SG 11202101042S A SG11202101042S A SG 11202101042SA SG 11202101042S A SG11202101042S A SG 11202101042SA SG 11202101042S A SG11202101042S A SG 11202101042SA SG 11202101042S A SG11202101042S A SG 11202101042SA
- Authority
- SG
- Singapore
- Prior art keywords
- gene therapy
- organ function
- therapy methods
- control organ
- control
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862712669P | 2018-07-31 | 2018-07-31 | |
PCT/US2019/044290 WO2020028466A1 (en) | 2018-07-31 | 2019-07-31 | Gene therapy methods to control organ function |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101042SA true SG11202101042SA (en) | 2021-02-25 |
Family
ID=69230802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101042SA SG11202101042SA (en) | 2018-07-31 | 2019-07-31 | Gene therapy methods to control organ function |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210301306A1 (en) |
EP (1) | EP3829718A4 (en) |
JP (2) | JP2021533126A (en) |
KR (1) | KR20210052450A (en) |
CN (1) | CN113301956A (en) |
AU (1) | AU2019315445A1 (en) |
BR (1) | BR112021001878A2 (en) |
CA (1) | CA3108324A1 (en) |
EA (1) | EA202190358A1 (en) |
IL (1) | IL280531A (en) |
MX (1) | MX2021001336A (en) |
PH (1) | PH12021550243A1 (en) |
SG (1) | SG11202101042SA (en) |
WO (1) | WO2020028466A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023019565A1 (en) * | 2021-08-20 | 2023-02-23 | 中国科学院深圳先进技术研究院 | Method for controlling heterogeneity of vascular endothelial cells by using sympathetic nerves |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US6342390B1 (en) | 1994-11-23 | 2002-01-29 | The United States Of America As Represented By The Secretary Of Health And Human Services | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy |
FR2814642B1 (en) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | TRANSGENIC MOUSE FOR THE TARGETED RECOMBINATION MEDIATED BY THE MODIFIED CRE-ER |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
WO2005110039A2 (en) | 2004-05-07 | 2005-11-24 | Applera Corporation | Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof |
GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
EP3200830B1 (en) * | 2014-10-03 | 2020-09-09 | University of Massachusetts | High efficiency library-identified aav vectors |
CA2998491A1 (en) * | 2015-09-17 | 2017-03-23 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
WO2017153995A1 (en) * | 2016-03-09 | 2017-09-14 | Assaf Fadi | Using dreadd for neuronal modulation in treating neuronal diseases |
MA44546B1 (en) * | 2016-06-15 | 2021-03-31 | Univ California | Variant adeno-associated viruses and methods of use |
WO2018008770A1 (en) * | 2016-07-06 | 2018-01-11 | 国立研究開発法人国立循環器病研究センター | Method for controlling peripheral nerve, method for developing function to alter function of nerve cell in organs excluding brain and spinal cord and others, novel method for preventing or treating disease, and medicine for application to peripheral nerves |
CA3158516A1 (en) * | 2019-10-22 | 2021-04-29 | Applied Genetic Technologies Corporation | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegeneative diseases or disorders |
-
2019
- 2019-07-31 KR KR1020217005554A patent/KR20210052450A/en active Search and Examination
- 2019-07-31 CA CA3108324A patent/CA3108324A1/en active Pending
- 2019-07-31 WO PCT/US2019/044290 patent/WO2020028466A1/en active Application Filing
- 2019-07-31 JP JP2021505674A patent/JP2021533126A/en active Pending
- 2019-07-31 SG SG11202101042SA patent/SG11202101042SA/en unknown
- 2019-07-31 BR BR112021001878-6A patent/BR112021001878A2/en unknown
- 2019-07-31 EA EA202190358A patent/EA202190358A1/en unknown
- 2019-07-31 US US17/264,752 patent/US20210301306A1/en active Pending
- 2019-07-31 CN CN201980065036.9A patent/CN113301956A/en active Pending
- 2019-07-31 MX MX2021001336A patent/MX2021001336A/en unknown
- 2019-07-31 AU AU2019315445A patent/AU2019315445A1/en active Pending
- 2019-07-31 EP EP19845335.9A patent/EP3829718A4/en active Pending
-
2021
- 2021-01-31 IL IL280531A patent/IL280531A/en unknown
- 2021-02-01 PH PH12021550243A patent/PH12021550243A1/en unknown
-
2024
- 2024-01-10 JP JP2024001612A patent/JP2024041871A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL280531A (en) | 2021-03-25 |
CA3108324A1 (en) | 2020-02-06 |
CN113301956A (en) | 2021-08-24 |
EA202190358A1 (en) | 2021-05-04 |
US20210301306A1 (en) | 2021-09-30 |
BR112021001878A2 (en) | 2021-04-27 |
AU2019315445A1 (en) | 2021-03-18 |
EP3829718A1 (en) | 2021-06-09 |
KR20210052450A (en) | 2021-05-10 |
EP3829718A4 (en) | 2022-06-22 |
WO2020028466A1 (en) | 2020-02-06 |
PH12021550243A1 (en) | 2021-11-22 |
MX2021001336A (en) | 2021-09-10 |
JP2021533126A (en) | 2021-12-02 |
JP2024041871A (en) | 2024-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268894A (en) | Therapeutic rna | |
IL259100B1 (en) | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use | |
IL282794A (en) | Therapeutic methods | |
GB201804255D0 (en) | Macrophage-based therapy | |
IL279685A (en) | Gene therapy | |
LT3612237T (en) | Gene therapy | |
GB201819853D0 (en) | Therapy | |
EP3568694A4 (en) | Targeted doxorubicin-gold nanoconjugates for tumor therapy | |
ZA201907279B (en) | Methods of pest control | |
EP3787693A4 (en) | Methods of gene therapy | |
GB201707212D0 (en) | Gene therapy for ciliopathies | |
IL280531A (en) | Gene therapy methods to control organ function | |
GB201817470D0 (en) | Gene therapy | |
GB201905301D0 (en) | Gene therapy | |
GB201802326D0 (en) | Gene therapy | |
GB201701968D0 (en) | Gene therapy | |
EP3760209C0 (en) | Ischemic-lesion-site-specific gene therapy | |
GB201820982D0 (en) | Gene Therapy | |
GB201811541D0 (en) | Gene therapy | |
GB201801511D0 (en) | Gene therapy | |
IL289338A (en) | Therapeutic interactions of leucomethylthioninium | |
GB201907647D0 (en) | Therapeutic methods | |
GB201904341D0 (en) | Therapeutic methods | |
GB201704634D0 (en) | Gene therapy | |
IL263085A (en) | Gene therapy |